161 related articles for article (PubMed ID: 15934876)
21. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
22. Emerging drugs in cutaneous T-cell lymphomas.
Dummer R
Expert Opin Emerg Drugs; 2005 May; 10(2):381-92. PubMed ID: 15934873
[TBL] [Abstract][Full Text] [Related]
23. [Second-line treatment using novel chemotherapeutic and biologic agents].
Sugiyama T
Gan To Kagaku Ryoho; 2009 May; 36(5):730-5. PubMed ID: 19461172
[TBL] [Abstract][Full Text] [Related]
24. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
26. Recent advances with topotecan in the treatment of lung cancer.
O'Brien M; Eckardt J; Ramlau R
Oncologist; 2007 Oct; 12(10):1194-204. PubMed ID: 17962613
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
Vergote I; Finkler N; del Campo J; Lohr A; Hunter J; Matei D; Kavanagh J; Vermorken JB; Meng L; Jones M; Brown G; Kaye S;
Eur J Cancer; 2009 Sep; 45(13):2324-32. PubMed ID: 19515553
[TBL] [Abstract][Full Text] [Related]
29. Topotecan: weighing in when there are many options.
Penson RT; Seiden MV
Oncologist; 2005 Oct; 10(9):698-700. PubMed ID: 16249349
[TBL] [Abstract][Full Text] [Related]
30. Emerging drugs for adult acute lymphoblastic leukaemia.
Thomas X
Expert Opin Emerg Drugs; 2005 Aug; 10(3):591-617. PubMed ID: 16083331
[TBL] [Abstract][Full Text] [Related]
31. [Chemotherapy of advanced ovarian carcinoma. II. Second-line treatment and new therapeutic modalities].
Angelini F; Carassai A; Lopez M
Clin Ter; 1989 Apr; 129(2):91-104. PubMed ID: 2472913
[TBL] [Abstract][Full Text] [Related]
32. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.
Colombo N; Gore M
Crit Rev Oncol Hematol; 2007 Nov; 64(2):129-38. PubMed ID: 17566758
[TBL] [Abstract][Full Text] [Related]
33. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.
de Bree E; Theodoropoulos PA; Rosing H; Michalakis J; Romanos J; Beijnen JH; Tsiftsis DD
Cancer Treat Rev; 2006 Oct; 32(6):471-82. PubMed ID: 16942841
[TBL] [Abstract][Full Text] [Related]
34. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
35. Emerging drugs for renal cell carcinoma.
Shaheen PE; Bukowski RM
Expert Opin Emerg Drugs; 2005 Nov; 10(4):773-95. PubMed ID: 16262562
[TBL] [Abstract][Full Text] [Related]
36. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Markman M
Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
[TBL] [Abstract][Full Text] [Related]
37. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
38. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in the treatment of epithelial ovarian cancer.
Harries M; Kaye SB
Expert Opin Investig Drugs; 2001 Sep; 10(9):1715-24. PubMed ID: 11772280
[TBL] [Abstract][Full Text] [Related]
40. Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ
J Clin Oncol; 2003 May; 21(10 Suppl):187s-193s. PubMed ID: 12743133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]